-
公开(公告)号：US09623091B2
公开(公告)日：2017-04-18
申请号：US15043455
申请日：2016-02-12
Applicant: Bioverativ Therapeutics Inc.
Inventor： Glenn Pierce , Samantha Truex , Robert T. Peters , Haiyan Jiang
IPC: A61K38/36 , A61K38/48 , A61K39/395 , C12N9/96 , A61K38/38 , C07K16/18 , C12N9/64 , C07K14/76 , A61K9/00 , A61K47/48
CPC classification number: A61K38/4846 , A61K9/0019 , A61K38/38 , A61K39/395 , A61K39/39533 , A61K39/3955 , A61K47/643 , C07K14/76 , C07K16/18 , C07K2317/21 , C07K2317/90 , C07K2317/94 , C07K2319/30 , C07K2319/31 , C07K2319/33 , C12N9/644 , C12N9/96 , C12Y304/21022
Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
-
公开(公告)号：US20250136640A1
公开(公告)日：2025-05-01
申请号：US18903305
申请日：2024-10-01
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Glen BOLTON , Keith SELVITELLI
IPC: C07K1/22 , A61L2/00 , C07K1/16 , C07K14/755 , C07K16/06
Abstract: The present invention is directed to a method of inactivating virus that is present during production of a polypeptide of interest. In particular, the present invention is directed to a method of on-column virus inactivation using a low pH and high salt wash solution that effectively inactivates viruses with minimum recovery loss of the polypeptide.
-
公开(公告)号：US20240124555A1
公开(公告)日：2024-04-18
申请号：US18364103
申请日：2023-08-02
Applicant: Bioverativ Therapeutics Inc.
Inventor： Siyuan TAN , Tongyao LIU
IPC: C07K14/755 , A61K48/00 , A61P7/04 , C12N7/00 , C12N15/86
CPC classification number: C07K14/755 , A61K48/0016 , A61K48/005 , A61P7/04 , C12N7/00 , C12N15/86 , A61K38/00 , C07K2319/30 , C07K2319/31 , C12N2740/16043 , C12N2800/22
Abstract: The present disclosure provides codon optimized Factor VIII sequences, vectors, and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides. The present disclosure also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor VIII nucleic acid sequence or the polypeptide encoded thereby.
-
公开(公告)号：US20230322900A1
公开(公告)日：2023-10-12
申请号：US18064571
申请日：2022-12-12
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Volker Schellenberger , Pei-Yun Chang , Fatbardha Varfaj , Sheng Ding , Joshua Silverman , Chia-wei Wang , Benjamin Spink , Willem P. Stemmer , Nathan Geething , John Kulman , Tongyao Liu , Garabet G. Toby , Haiyan Jiang , Robert Peters , Deping Wang , Baisong Mei
IPC: C07K14/755
CPC classification number: C07K14/755 , A61K38/00
Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
-
公开(公告)号：US20230310560A1
公开(公告)日：2023-10-05
申请号：US18184821
申请日：2023-03-16
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Mark BRADER
IPC: A61K38/48 , A61K9/00 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/22 , A61K47/26 , A61M5/158 , A61M5/178 , A61M5/19
CPC classification number: A61K38/4846 , C12Y304/21022 , A61K9/0019 , A61K9/19 , A61K47/02 , A61K47/10 , A61K47/22 , A61K47/26 , A61M5/158 , A61M5/178 , A61M5/19 , C07K2319/30
Abstract: The present invention provides formulations comprising a Factor IX—FcRn Binding Partner (FIXFBP) polypeptide, and methods of administering FIXFBP.
-
Patent Agency Ranking
公开(公告)号：US11753461B2
公开(公告)日：2023-09-12
申请号：US16074729
申请日：2017-01-31
Applicant: Bioverativ Therapeutics Inc.
Inventor： Siyuan Tan , Tongyao Liu
IPC: C07H21/04 , C12N15/00 , C12N15/63 , A61K31/70 , C07K14/755 , A61K48/00 , C12N15/86 , A61P7/04 , C12N7/00 , A01K67/00 , A61K38/00
CPC classification number: C07K14/755 , A61K48/005 , A61K48/0016 , A61P7/04 , C12N7/00 , C12N15/86 , A61K38/00 , C07K2319/02 , C07K2319/30 , C07K2319/31 , C12N2740/15043 , C12N2740/16043 , C12N2800/22
Abstract: The present disclosure provides codon optimized Factor VIII sequences, vectors, and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides. The present disclosure also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor VIII nucleic acid sequence or the polypeptide encoded thereby.
-
公开(公告)号：US20230091932A1
公开(公告)日：2023-03-23
申请号：US17821356
申请日：2022-08-22
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Ajay Maghodia , Christian Mueller , Tongyao Liu
IPC: C12N15/113 , C12N15/86 , C07K14/755 , A61K31/713
Abstract: The present disclosure provides nucleic acid molecules comprising a first inverted terminal repeat (ITR), a second ITR, and a genetic cassette encoding a target sequence. In some embodiments, the first ITR and/or the second ITR is an ITR of human bocavirus. Also disclosed are methods of using the nucleic acid molecules in gene therapy applications.
-
公开(公告)号：US11578098B2
公开(公告)日：2023-02-14
申请号：US16793676
申请日：2020-02-18
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Glen Bolton , Keith Selvitelli
Abstract: The present invention is directed to a method of inactivating virus that is present during production of a polypeptide of interest. In particular, the present invention is directed to a method of on-column virus inactivation using a low pH and high salt wash solution that effectively inactivates viruses with minimum recovery loss of the polypeptide.
-
公开(公告)号：US20230019286A1
公开(公告)日：2023-01-19
申请号：US17240351
申请日：2021-04-26
Applicant: Bioverativ Therapeutics Inc.
Inventor： Volker SCHELLENBERGER , Pei-Yun CHANG , Fatbardha VARFAJ , John KULMAN , Tongyao LIU , Garabet G. TOBY , Haiyan JIANG , Robert PETERS , Deping WANG , Baisong MEI , Joshua SILVERMAN , Chia-Wei WANG , Benjamin SPINK , Nathan GEETHING
IPC: C07K14/755 , C07K14/00
Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
-
公开(公告)号：US11372008B2
公开(公告)日：2022-06-28
申请号：US15979349
申请日：2018-05-14
Applicant: Bioverativ Therapeutics Inc.
Inventor： Jurg Sommer
Abstract: The present disclosure provides methods and compositions for diagnosing and treating subject having a bleeding disorder. The disclosed methods comprise contacting a sample, e.g., a blood or plasma sample obtained from the patient, with an activation mixture comprising an activated coagulation factor and a phospholipid mixture, wherein the activation mixture is dried onto a solid substrate. Also provided is a global hemostasis test based on the integration of clotting time (Ct) and pharmacokinetics data. The methods and compositions presented can be applied to point-of-care diagnostic systems.
-
-
-
-
-
-
-
-
-
Search Results
158
records
(took 0.021 seconds)
